Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Net Cash Flow (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Net Cash Flow data on record, last reported at $2.1 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 139.99% year-over-year to $2.1 million; the TTM value through Sep 2025 reached -$3.1 million, down 142.7%, while the annual FY2024 figure was -$884244.0, 122.12% down from the prior year.
  • Net Cash Flow reached $2.1 million in Q3 2025 per GANX's latest filing, up from -$2.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $39.2 million in Q1 2021 and bottomed at -$19.9 million in Q2 2022.
  • Average Net Cash Flow over 5 years is $48668.4, with a median of -$1.9 million recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 6065.83% in 2021, down 694.42% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$4.2 million in 2021, then rose by 8.99% to -$3.8 million in 2022, then surged by 285.69% to $7.0 million in 2023, then crashed by 116.83% to -$1.2 million in 2024, then soared by 277.72% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $2.1 million in Q3 2025, -$2.6 million in Q2 2025, and -$1.4 million in Q1 2025.